Invesaro

Stocks GMAB Financial statements

Financial statements

GENMAB A/S financial statements

Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data GENMAB A/S files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

FY2023FY2025FY2025
Revenue2,3903,1213,720
Cost of revenue33143238
Gross profit2,3572,9783,482
Research and development1,1071,4141,606
Selling, general and administrative478549626
Operating income7729721,065
Interest expense254291269
Interest income299645408
Pre-tax income8171,3261,204
Income tax186193241
Net income6311,133963
EPS, basic9.6717.6615.50
EPS, diluted9.5817.5315.37

Balance sheet

FY2023FY2025FY2025
Cash and equivalents2,2041,3801,715
Receivables7339231,112
Inventory8918
Total current assets4,9123,9002,885
Property, plant and equipment142137153
Lease right-of-use assets102128127
Goodwill0355355
Intangible assets151,7289,123
Total assets5,2326,41412,873
Total current liabilities3687441,427
Lease liabilities101131134
Total liabilities5451,2777,026
Total debt05,274
Paid-in capital1,9421,9611,920
Retained earnings2,7373,3924,098
Total equity4,6875,1375,847
Total liabilities and equity5,2326,41412,873

Cash flow statement

FY2023FY2025FY2025
Net income6311,133963
Cash from operations1,0711,1261,186
Capital expenditures-53-27-37
Cash from investing-185-1,447-5,643
Debt issued005,500
Debt repaid00-273
Cash from financing-89-5664,789
Exchange rate effect-12633
Free cash flow1,0181,0991,149
Interest paid005

Key metrics

Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $35.36 on September 28, 2026.

Profitability

MetricValueHow it is calculated
Gross margin93.6%Gross profit / revenue.
Operating margin28.6%Operating income / revenue.
Pre-tax margin32.4%Pre-tax income / revenue.
Net margin25.9%Net income / revenue.
FCF margin30.9%Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin31.9%Cash from operations / revenue.
Effective tax rate20.0%Income tax / pre-tax income, when pre-tax income is positive.
Return on assets (ROA)10.0%Net income / average total assets.
R&D / revenue43.2%Research and development expense / revenue.
SG&A / revenue16.8%Selling, general and administrative expense / revenue.
Capex / revenue1.0%Capital expenditures / revenue.

Growth

MetricValueHow it is calculated
Revenue growth, 1y19.2%Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y16.9%Gross profit vs the same period a year earlier. Only from a positive base.
Operating income growth, 1y9.6%Operating income vs the same period a year earlier. Only from a positive base.
Net income growth, 1y-15.0%Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y-12.3%EPS vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y5.3%Operating cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow growth, 1y4.5%Free cash flow vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y100.7%Total assets vs the same period a year earlier. Only from a positive base.

Balance sheet health

MetricValueHow it is calculated
Current ratio2.02xCurrent assets / current liabilities.
Quick ratio1.98x(Cash + short-term investments + receivables) / current liabilities.
Cash ratio1.20x(Cash + short-term investments) / current liabilities.
Debt / assets41.0%Total debt / total assets.
Liabilities / assets54.6%Total liabilities / total assets.
Net debt$3.56BTotal debt - cash - short-term investments. Negative means more cash than debt.
Interest coverage3.96xOperating income / interest expense.
Working capital$1.46BCurrent assets - current liabilities.
Goodwill and intangibles / assets73.6%(Goodwill + intangible assets) / total assets.

Efficiency

MetricValueHow it is calculated
Asset turnover0.39xRevenue / average total assets.
Fixed asset turnover25.7xRevenue / average property, plant and equipment.
Inventory turnover17.6xCost of revenue / average inventory.
Days inventory21 days365 x average inventory / cost of revenue.
Receivables turnover3.66xRevenue / average receivables.
Days sales outstanding100 days365 x average receivables / revenue.
FCF conversion119.3%Free cash flow / net income, when net income is positive.
Capex / operating cash flow3.1%Capital expenditures / cash from operations, when that is positive.

Per share

MetricValueHow it is calculated
EPS, diluted$15.37Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic$15.50Net income per basic share, as reported (split-adjusted).

Valuation

MetricValueHow it is calculated
Market cap$4.54BShare price x shares outstanding.
Enterprise value$8.10BMarket cap + total debt - cash - short-term investments.
P/E4.72xMarket cap / net income. Only when net income is positive.
P/S1.22xMarket cap / revenue.
P/FCF3.95xMarket cap / free cash flow. Only when free cash flow is positive.
P/OCF3.83xMarket cap / cash from operations, when positive.
EV/Sales2.18xEnterprise value / revenue.
EV/EBIT7.61xEnterprise value / operating income, when both are positive.
EV/FCF7.05xEnterprise value / free cash flow, when both are positive.
FCF yield25.3%Free cash flow / market cap.
Earnings yield21.2%Net income / market cap (the inverse of P/E).
What was GENMAB A/S's revenue in fiscal 2025?

GENMAB A/S reported revenue of $3.72B for fiscal 2025, 19.2% higher than the year before.

Was GENMAB A/S profitable in fiscal 2025?

Yes. Net income was $963.0M, a net margin of 25.9%.

How much free cash flow did GENMAB A/S generate in fiscal 2025?

Cash from operations of $1.19B minus capital expenditures of $37.0M left free cash flow of $1.15B.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to GENMAB A/S